GSK, Theravance's new COPD drug moves to Phase III testing
- GSK and Theravance have developed a triple therapy delivered through a single inhaler for treatment of chronic obstructive pulmonary disorder (COPD), and are currently moving into phase III trials.
- The new therapy is a combination of fluticasone furoate, umeclidinium and vilanterol.
- The goal of the phase III study, which includes 10,000 patients, is to test the three-in-one combo against established dual-medication treatments, including Relvar/Breo (FF/VI) and Anoro Ellipta (UMEC/VI).
The primary endpoint of this study, known as the IMPACT study, is to evaluate whether the new three-in-one inhaled drug may reduce moderate and severe COPD exacerbations more effectively than existing dual-drug medications.
“[W]e know from the scientific literature and prescribing data that there are already COPD patients who receive three medicines in different inhalers, for whom a once-daily treatment in a single 'closed' device could be valuable," said Dave Allen, head of respiratory R&D at GSK.